Drugs / F-18 16 Alpha-Fluoroestradiol
F-18 16 Alpha-Fluoroestradiol
also known as
\[18F\]FES · 16α-\[18F\]fluoro-17β-estradiol · [F-18] FES · Fluoroestradiol (18F) · 16-alpha-18F-fluoro-17-beta-estradiol · FES
Trials 13
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 13 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | F-18 16 Alpha-Fluoroestradiol | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04692103 ↗ |
| Known as | 16-alpha-18F-fluoro-17-beta-estradiol | “16-alpha-18F-fluoro-17-beta-estradiol(FES) is a radiolabeled form of estrogen binding to functionally active ER which will be used as radiotracer for the PET/MRI exam” NCT05982496 ↗ |
| Known as | 16α-\[18F\]fluoro-17β-estradiol | “16α-\[18F\]fluoro-17β-estradiol (\[18F\]FES) is currently the only ER-targeted PET agent validated in previous clinical trials.” NCT03544762 ↗1“Pilot Study Evaluating Endometriosis With 16α-(18)F-fluoro-17β-estradiol ([F-18] FES) PET/MRI” NCT04347135 ↗ |
| Known as | [F-18] FES | “Pilot Study Evaluating Endometriosis With 16α-(18)F-fluoro-17β-estradiol ([F-18] FES) PET/MRI” NCT04347135 ↗ |
| Known as | \[18F\]FES | “16α-\[18F\]fluoro-17β-estradiol (\[18F\]FES) is currently the only ER-targeted PET agent validated in previous clinical trials.” NCT03544762 ↗ |
| Known as | FES | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05982496 ↗ |
| Known as | Fluoroestradiol (18F) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03507088 ↗ |
| Modality | Diagnostic / imaging agent | “evaluate diagnostic performance of FES PET/CT” NCT01627704 ↗ |
| Route | Intravenous | “one single IV injection” NCT01627704 ↗ |